Protein kinase CK2 is a ubiquitous serine-threonine kinase in which a catalytic a subunit often associates with a b subunit. CK2a is required for cell survival in yeast and has been proposed to be involved in cell growth control; however, its regulation in cells remains unclear.
Introduction
Protein kinase CK2 (formerly casein kinase 2) is a ubiquitous serine/threonine kinase which modi®es an extensive range of enzymes and regulatory proteins at functionally relevant sites. These include multiple cellular and viral transcription factors; splicing and translation factors; cytoskeletal proteins; phosphatase inhibitors; and DNA-modifying enzymes (reviewed by Allende and Allende, 1995) . Thus, as CK2 phosphorylates potent growth regulators, is found in all eukaryotic cells, and displays exceptionally high sequence conservation, regulation by this kinase is presumably critical.
CK2 was ®rst described as an heterotetramer of two catalytic (a) and two regulatory (b) subunits (Glover et al., 1983) . However, it has also been reported that CK2a can exist independently of CK2b (Stigare et al., 1993; Schmidt-Spaniol et al., 1993 ) but yet no regulation of the association between the two subunits has been uncovered. We recently identi®ed CK2a as a negative regulator of the MAPK pathway. This function of CK2a is mediated through association between CK2b-free CK2a and protein phosphatase 2A (PP2A). In quiescent cells, the association of CK2a with PP2A stimulates the phosphatase activity towards MAP/ERK kinase 1 (MEK1) whereas mitogen stimulation of the cells disrupts the CK2a/PP2A complex allowing MEK1 activation (HeÂ richeÂ et al., 1997) .
From a comprehensive survey of the protein kinase superfamily (Hanks and Hunter, 1995) , it appears that CK2a belongs to the same evolutionary branch as glycogen synthase kinase-3 (GSK-3). Other studies suggest that GSK-3 and CK2a also share some functional attributes. GSK-3 has been shown to be activated by tyrosine phosphorylation in quiescent cells (Hughes et al., 1993) and inhibited by kinases downstream of Ras (Eldar-Finkelman et al., 1995) . CK2a is also constitutively active in unstimulated cells and acts downstream of Ras to regulate the MAPK pathway (HeÂ richeÂ et al., 1997). The two kinases sometimes cooperate in multisite phosphorylation (Picton et al., 1982; DePaoli-Roach, 1984) , suggesting responsiveness to common stimuli. These similarities raise the possibility that CK2a might share other characteristics with GSK-3 and prompted us to examine whether CK2a, like GSK-3, could be regulated by tyrosine phosphorylation.
Here we provide evidence that CK2a could be regulated by the c-Abl and oncogenic Bcr ± Abl tyrosine kinases.
Results

CK2a is phosphorylated on tyrosine by an associated kinase
We ®rst examined if CK2a were phosphorylated on tyrosine in quiescent cells. HA-tagged CK2a was overexpressed in NIH3T3 cells and the transfected cells were serum-deprived. CK2a-HA was then immunoprecipitated by anti-HA under denaturing conditions and probed by Western blotting with an anti-phosphotyrosine antibody. As shown in Figure 1a , CK2a-HA reacts with the PY20 monoclonal antiphosphotyrosine antibody. This indicates that CK2a can be phosphorylated by a tyrosine kinase in quiescent cells. Identical results were obtained using the 4G10 anti-phosphotyrosine antibody (not shown).
To characterize protein kinase responsible for CK2a phosphorylation, we asked whether CK2a could be substrate for an associated tyrosine kinase. Anti-HA immunoprecipitates from quiescent CK2a-HA-transfected cells were incubated with Mg
2+
, Mn 2+ and [g SDS ± PAGE. Before autoradiography, the proteins were transferred to an Immobilon membrane and treated with hot KOH to remove phosphates from serine and threonine residues so that phospho-tyrosines were revealed (Cooper and Hunter, 1981) . Following this procedure, phosphorylated CK2a was recovered in immunoprecipitates containing CK2a-HA or a kinaseinactive mutant (CK2aK68A-HA) but not in control immunoprecipitates from CK2a transfected cells (Figure 1b) . The presence of phosphorylated kinaseinactive CK2a shows that this phosphorylation is due to a kinase other than CK2a. This supports the idea that CK2a associates with a tyrosine kinase in quiescent cells. This was also con®rmed as anti-HA immunoprecipitates containing either wild-type or kinase inactive CK2a could also phosphorylate a tyrosine-containing synthetic peptide (data not shown).
CK2a is an Abl substrate in vitro
When anti-HA immunoprecipitates from quiescent CK2a-HA-transfected cells were incubated with [g 32 P]ATP and resolved by SDS ± PAGE, some high molecular weight phosphorylated bands (4100 kDa) were observed (Figure 2a ). This lead us to look for a tyrosine kinase of over 100 kDa. As c-Abl has a molecular weight of 120 kDa, we asked if it could phosphorylate CK2a in vitro. We incubated bacterially produced puri®ed GST-fused, HA-tagged wildtype GST-CK2a-HA or kinase-inactive GSTCK2aK68A-HA with a bacterially produced catalytic domain of c-Abl in the presence of Mg
2+
, Mn 2+ and [g 32 P]ATP. After reaction, CK2a was repuri®ed on a glutathione column and analysed by autoradiography. The catalytic domain of c-Abl phosphorylated CK2a (Figure 2b ). Thus, in vitro, GST-CK2a-HA is a substrate for the tyrosine kinase. No change in CK2a activity could be seen after phosphorylation presumably due to the thermal instability of puri®ed recombinant CK2a (Meggio et al., 1992 ; and data not shown). It may be noticed that high concentrations of CK2a were found to inhibit CK2a phosphorylation by Abl and a representative sigmoid-like curve was obtained when plotting CK2a phosphorylation as a function of CK2a concentration suggesting an allosteric mechanism for the reaction ( Figure 2c ).
CK2a associates with c-Abl and Bcr ± Abl in vivo
To determine if c-Abl is the CK2a-associated tyrosine kinase in cells, anti-Abl immunoprecipitates obtained from NIH3T3 and Abl 7/7 3T3 ®broblasts were analysed by Western blot with an anti-CK2a antibody ( Figure 3a ). While immunoprecipitates from Abl 7/7 ®broblasts yielded no CK2a (lane 3), CK2a could be detected in anti-Abl precipitates from NIH3T3 cells (lane 2). This experiment indicated that CK2a was indeed associated with c-Abl in NIH3T3 cells. Abl-associated CK2a represented about 1% of total CK2a. As c-Abl is a protooncogene, we tested whether CK2a could also associate with the oncogenic form of the tyrosine kinase. NIH3T3 cells were cotransfected with plasmids expressing p190Bcr ± Abl and CK2a. Bcr ± Abl was then immunoprecipitated from the lysates using an anti-Bcr antibody. Analysis of the precipitates by Western blot with an anti-CK2a antibody revealed the presence of CK2a in the immunoprecipitate only when Bcr ± Abl was present indicating that CK2a is speci®cally associated with Bcr ± Abl in these extracts (Figure 3b) . The Bcr ± Abl fusion protein plays a major role in chronic myelogenous leukemia. We thus tested whether the complex exists in leukemia-derived cells. Anti-Bcr immunoprecipitates were obtained from K562 cells. These precipitates also reacted with an anti-CK2a antibody (Figure 3c) . Thus, the Bcr ± Abl/CK2a complex also exists in a chronic myelogenous leukemia cell line expressing the p210Bcr ± Abl fusion protein. In these cells, between 5 and 10% of total CK2a was associated with Bcr ± Abl.
Bcr ± Abl induces inhibition of CK2a
We next addressed the question as to whether Bcr ± Abl overexpression may aect CK2a activity. CK2a-HA was cotransfected with empty vector or Bcr ± Abl Reactions were stopped by boiling in 2% SDS. The mixture was then diluted in RIPA buer and subjected to a second anti-HA immunoprecipitation. Recovered proteins were resolved by SDS ± PAGE, transferred to Immobilon P membrane and treated with 1 N KOH at 608C for 1 h and autoradiographed with a PhosphorImager in NIH3T3 cells. CK2a activity was then assayed in anti-HA immunoprecipitates. CK2a speci®c activity was 50% lower in the presence of Bcr ± Abl than in its absence (Figure 4, lanes 1 and 2) . Incubation with recombinant tyrosine phosphatase PTP-1B, but not buer alone, restored CK2a activity (lane 4) which suggests that inhibition is due to tyrosine phosphorylation of CK2a. Thus, like the related kinase GSK-3, CK2a responds to tyrosine phosphorylation although CK2a is inhibited whereas GSK-3 is activated (Hughes et al., 1993) .
Discussion
CK2 is supposed to play a critical role in growth control and many of its substrates are growth regulators. However CK2 activity appears to be insensitive to extracellular signals. In the present study, we investigated the possibility that CK2 may be a target for tyrosine phosphorylation by analogy to what has been established for the phylogenetically related kinase GSK-3. By probing CK2a with antiphosphotyrosine antibodies, we found that like GSK-3, CK2a could be phosphorylated on tyrosine in quiescent cells. However, radioactive phosphate labeling of quiescent NIH3T3 cells did not yield detectable radiolabeled CK2a (data not shown). One possible explanation for this discrepancy is that CK2a phosphorylation has a low turnover in quiescent cells. In spite of this, in vivo tyrosine phosphorylation of CK2a is likely in view of the ®nding that CK2a is associated with various forms of the Abl tyrosine kinase in living cells and that this tyrosine kinase can phosphorylate CK2a in vitro. As puri®ed recombinant CK2a is markedly unstable in vitro (it loses activity within a few minutes at 208C), we could not see any change in CK2a activity following phosphorylation by Abl. Nevertheless, in cells, CK2a is downregulated in the presence of the Bcr ± Abl oncogenic tyrosine kinase. This inhibition seems to be mediated by tyrosine phosphorylation of CK2a since incubation with a tyrosine phosphatase restores CK2a activity. That CK2a is inhibited by tyrosine phosphorylation is somewhat surprising as the reverse was expected from the similarities with GSK-3. However, CK2a inhibition could be indirect if binding to Abl targets CK2a to another tyrosine kinase. Alternatively, phosphorylation by Abl could cooperate with phosphorylation by another kinase to inactivate CK2a. In such a case, dephosphorylation of one of the two sites would reactivate the kinase. The bulk of CK2 activity is not sensitive to extracellular signals which lead some authors to propose that CK2 is an unregulated kinase (Litch®eld et al., 1994) . The present data suggest the novel possibility that CK2a activity can be regulated by a post-translational mechanism in response to extracellular signals. More investigation will be needed in order to determine what signals govern CK2a activity in various subpopulations of CK2. We recently found that CK2b-free CK2a controls the rate of MEK1 deactivation through its association with PP2A in a growth factor-dependent manner (HeÂ richeÂ et al., 1997) . Interestingly, it has also recently been shown that MEK1 activation, but not Raf activation, depends on cell adhesion (Renshaw et al., 1997) . Since the cytoplasmic fraction of Abl tyrosine kinase has been implicated in adhesion signaling (Lewis et al., 1996) and the oncogenic Bcr ± Abl has been shown to suppress anchorage dependence (Renshaw et al., 1995) these data, taken together, suggest that Abl-associated CK2a might integrate adhesion signals into the MAP kinase cascade at the level of MEK1. In normal cells, c-Abl phosphorylation of CK2a might be necessary for CK2a response to growth factors thus preventing MEK1 activation if the cells are not adherent. By inactivating CK2a, the constitutively activated oncogenic tyrosine kinase Bcr ± Abl would thus provide a constitutive adhesion signal input into the MAP kinase pathway. Alternatively, by directly repressing CK2a, Abl would in¯uence the kinetics of MEK1 activation. This parameter is critical in determining cell fate in response to extracellular signals. In the Bcr ± Abl expressing cell line K562, chronic MEK1 activity leads to megakaryocytic dierentiation (Whalen et al., 1997) . Since the MAP kinase pathway seems to control the dierentiation state of this cell line, Bcr ± Abl inhibition of CK2a activity might contribute to the undierentiated phenotype of myeloid cell lines by modifying the MAP kinase cascade kinetics of response to extracellular signals. 6 NIH3T3 cells were cotransfected with 6 mg of a Bcr ± Abl expressing plasmid (lanes 2 and 4) or empty vector (lanes 1 and 3) in the presence of 4 mg of a CK2a-HA expressing plasmid. Cells were made quiescent by serum-starvation for 24 h. CK2a-HA was recovered from the lysates by anti-HA immunoprecipitation. The immunoprecipitates were split in two and incubated either with 0.5 mg GST-PTP-1B (lanes 3 and 4) or buer alone (lanes 1 and 2) for 15 min at room temperature. After reaction, the precipitates were washed and assayed for CK2a activity using a speci®c peptide substrate. Background activity was determined using anti-HA immunoprecipitates from cells transfected with untagged CK2a. Shown are the means+s.e.m. of three experiments
Materials and methods
Plasmid construction
Chicken CK2a cDNA (kindly provided by E Nigg) was modi®ed by PCR to include a 5' Kozak consensus sequence (Kozak, 1988) and, when needed, a 3' HA epitopeencoding sequence (Wilson et al., 1984) . The modi®ed cDNAs were cloned in pSG5 to give pSGa and pSGa-HA. The CK2aK68A mutant was generated by PCR-directed mutagenesis (Mikaelian and Sergeant, 1992) , and the mutation was cloned by cassette replacement into pSGa and pSGa-HA to give pSGaK68A and pSGaK68A-HA, respectively. The plasmid pKJ1Bcr-Abl expressing the p190 Bcr ± Abl protein is a gift from Dr Turhan.
Recombinant protein expression and puri®cation
GST-CK2a-HA and GST-CK2aK68A-HA were expressed in E. coli BL21 and puri®ed by glutathione-Sepharose chromatography (Pharmacia), as recommended by the manufacturer. The recombinant catalytic domain of the Abl tyrosine kinase (amino-acids 237 ± 643 of v-Abl) was purchased from New England Biolabs (Beverly, MA). Recombinant GST-fused PTP-1B was from Upstate Biotechnology Inc. (Lake Placid, NY) and was eluted from the gluthatione-sepharose beads in 20 mM HEPES pH 7.4, 10 mM glutathione, 0.1% b-mercaptoethanol.
Antibodies
Anti-Abl (Ab3) was from Oncogene Research Products (Cambridge, MA). Anti-Abl (K12) and anti-Bcr (G6) were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-HA 12CA5 ascites¯uid was from BabCo (Richmond, CA). Anti-phosphotyrosine PY20 was from Transduction Laboratories (Lexington, KY).
Phosphorylations
For Abl-mediated phosphorylations, incubations were done with 50 U recombinant Abl in 50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 10 mM MnCl 2 , 1 mM DTT, 0.015% Brij 35, 100 mM [g 32 P]ATP (5000 ± 7000 c.p.m./pmole) at 308C for the indicated durations. After reaction, GST-CK2a-HA was repuri®ed on gluthatione-sepharose, resolved by SDS ± PAGE and autoradiographed with a PhosphorImager. CK2a activity was assayed by incubating immunoprecipitates in 30 ml kinase buer (20 mM Tris-Hcl pH 7.5, 10 mM MgCl 2 , 0.1 mM EGTA, 0.1% b-mercaptoethanol, 30 mM [g 32 P]ATP (10 4 c.p.m./pmol), 0.1 mM Na 3 VO 4 ) at room temperature for 10 min with the RRREDEESDDEE peptide (150 mM) as a substrate. Incorporated radioactivity was determined using the phosphocellulose paper method.
Cell culture and transfections
NIH3T3 and Abl
7/7 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). Calcium phosphate coprecipitations were normalized to 20 mg expression vector per 10 cm dish or 10 mg per 6 cm dish. K562 cells were maintained in RPMI 1640 medium supplemented with 10% FCS.
Immunoprecipitations and Western blotting
Cells were washed once with ice-cold phosphate-buered saline (PBS) and lysed in 1 ml Triton buer (20 mM TrisHcl pH 7.5, 100 mM NaCl, 50 mM NaF, 1% Triton X100, 0.1% b-mercaptoethanol, 25 mg/ml aprotinin, 25 mg/ml leupeptin, 0.1 mM Na 3 VO 4 ). Lysates were cleared by centrifugation at 12 000 g for 10 min, then incubated with 8 mg of the indicated antibody for 1 h at 48C. Immunoprecipitates were collected for 40 min at 48C on protein GSepharose (Pharmacia), then washed four times with lysis buer.
For denaturing immunoprecipitations, cells were lysed with 100 ml 1% SDS and boiled for 2 min. The lysate was diluted tenfold in RIPA buer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% deoxycholate, 1% Triton X100, 0.1 mM Na 3 VO 4 ) and clari®ed by centrifugation (15 min, 13 000 g) before adding the antibody. Precipitates were washed three times in RIPA buer containing 0.5 M NaCl.
For Western blotting, anti-CK2a serum was diluted to 1 : 1000. Blots were revealed by chemiluminescence (ECL, Amersham, UK).
